FIBRONOSTICS

LIVERFASt

Blood-based liver evaluation test that uses
10 biomarkers and advanced technology to determine
the condition the liver

What is LIVERFASt™?

LIVERFASt™ provides a score from 0.00 to 1.00 and its estimated grade or stage, similar to

 the histopathological scoring of the liver (based on the liver biopsy classification).

How it Works

Simple and easy-to-do

Physician prescribes
LIVERFASt™

Lab analyzes
10 biomarkers from
1 blood draw

Biomarker values plus age,
height, weight, gender,
are
entered into the platform

LIVERFASt™ results
are available
immediately

Physician prescribes
LIVERFASt™

Lab analyzes
10 biomarkers from
1 blood draw

Biomarker values plus age,
height, weight, gender,
are
entered into the platform

LIVERFASt™ results
are available
immediately

What does LIVERFASt™ Measure?

LIVERFASt™ takes inputs from 10 biomarkers and patient anthropometrics to generate a

 score from 0.00 to 1.00 that corresponds to the histopathological staging of a liver biopsy.

Fibrosis

STAGE

INTERPRETATION

FO

No fibrosis

F1

Mild fibrosis

F2

Advanced fibrosis

F1

Significant fibrosis

F4

Severe fibrosis/cirrhosis

Activity

STAGE

INTERPRETATION

aO

No activity

a1

Mild activity

a2

Moderate activity

a1

Marked activity

a4

Severe activity

Steatosis

STAGE

INTERPRETATION

sO

No steatosis (<5%)

s1

Mild steatosis(5-33%)

s2

Moderate steatosis(34-66%)

s3

Marked steatosis (≥ 67%)

Clinical Validation

LIVERFASt™ is clinically validated against different cohorts, and can

be used to test patients wit different comorbidities

LIVIRFASt has high clinical performance for Fibrosis & Activity

LIVIRFASt Activity Test performance

MASLD population(n=223)

ADRDC (95%CI)
079.(0.71-0.85)
Specificity
0.85
Sensitivity
0.59
Negative Predictive Value

0.65

Positive Predictive Value
0.85

LIVIRFASt Fibrosis Test performance

MASLD population(n=223)

ADRDC (95%CI)
0.867(0.807-0.910)
Specificity
0.85
Sensitivity

0.75

Negative Predictive Value

0.88

Positive Predictive Value

0.71

The concordance for cirrhosis with Liver Biopsy (n=452)

LIVERFASt

LSM

FIB-4

67/95(71%)

51/95(54%)

45/95(47%)

Integration and Usability

LIVERFASt™ seamlessly integrates into any clinical or healthcare setting, enhancing liver health screening workflows without disrupting existing systems

Interested in LIVERFASt™?

Sign up with us to receive exclusive brochures and posters that provide detailed insights into groundbreaking products.

Let’s Keep in Touch!

Submit your email below to receive email updates
on events, new product releases and more!

For further inquiry, please contact us at: service@fibronostics.com
For clinical and medical enquiries, contact us at: medicalaffairs@fibronostics.com